Despite promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from managed care entities. The companies are https://emiliejnsb445085.thelateblog.com/42373313/copyright-s-vyndamax-faces-is-encountering-pbm-obstacles-the-look-of-access-fights